CLINICAL TRIALS PROFILE FOR TASIMELTEON
✉ Email this page to a colleague
All Clinical Trials for TASIMELTEON
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01163032 ↗ | Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder | Completed | Vanda Pharmaceuticals | Phase 3 | 2010-08-01 | The purpose of this study is to evaluate the efficacy and safety of a six month double-mask treatment of tasimelteon or placebo in male and female subjects with Non-24-Hour Sleep-Wake Disorder |
| NCT01218789 ↗ | Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception | Unknown status | Vanda Pharmaceuticals | Phase 3 | 2010-09-01 | The purpose of this study is to evaluate the safety of a one year open-label treatment of tasimelteon in male and female subjects with Non-24-Hour Sleep-Wake Disorder. |
| NCT01271387 ↗ | Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment | Completed | Vanda Pharmaceuticals | Phase 1 | 2011-01-01 | The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon (including its breakdown products) in the blood in individuals with mild or moderate liver disease compared to individuals who have normal liver function. |
| NCT01402076 ↗ | A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects | Completed | Vanda Pharmaceuticals | Phase 1 | 2011-08-01 | The purpose of this research study is to understand whether there is any difference in the amount of midazolam (including its breakdown product) in the blood when midazolam is given with tasimelteon, and whether there is any difference in the amount of rosiglitazone in the blood when rosiglitazone is given with tasimelteon. |
| NCT01428661 ↗ | Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder | Completed | Vanda Pharmaceuticals | Phase 2/Phase 3 | 2011-09-01 | The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder. |
| NCT01429116 ↗ | Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception | Completed | Vanda Pharmaceuticals | Phase 3 | 2011-10-01 | The purpose of this study is to evaluate the safety of tasimelteon in male and female patients who suffer from Non-24-Hour Sleep-Wake Disorder. |
| NCT01430754 ↗ | Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder | Completed | Vanda Pharmaceuticals | Phase 3 | 2011-09-01 | The purpose of this study is to evaluate the maintenance effect and safety of 20 mg tasimelteon versus placebo in subjects suffering from Non-24-Hour Sleep-Wake Disorder. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TASIMELTEON
Condition Name
Clinical Trial Locations for TASIMELTEON
Trials by Country
Clinical Trial Progress for TASIMELTEON
Clinical Trial Phase
Clinical Trial Sponsors for TASIMELTEON
Sponsor Name
